To address these concerns, we have previously proposed and reported application of myoblast therapy for DMD based on our well-established cell fusion technology (Siemionow et al. 2018a, 2018b), and created a new line of human dystrophin expressing chimeric (DEC) cells via ex-vivo fusion of human myoblasts from normal and DMD-affected donors. The gene discussed is DMD; the disease is Duchenne muscular dystrophy.